ArticleOpen access journal of clinical trials2020

MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease.

Boris Decourt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.